White matter hyperintensities and neuropsychiatric symptoms in mild cognitive impairment and Alzheimer’s disease
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2020
- Source ID
- 10.1016/j.nicl.2020.102367
Entities
People
- D. Louis Collins
- Karen Misquitta
- Mahsa Dadar
- Maria Carmela Tartaglia
Organizations
- AbbVie
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eisai
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Hoffmann-La Roche
- Johnson & Johnson
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Perrigo Company Plc
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Southern California